Clinuvel's Scenese (afamelanotide) is approved for listing by FDA

recently, the u.SFDA(http://announced the approval of Clinuvel(http://development of Scenesse (http:// to treat adult patients with skin damage caused by red blood cell-generating protosin rickets
about Afamelaide
a black skin quality-1 receptor agonistAfamelanotide is asynthetic(http://polypeptide, a similar to the alpha-melanocyte stimulation hormone (alpha-MSH)Alpha-MSH is a naturally occurring peptide hormone in the human bodyAfamelanotide is released by skin cells under the stimulation of ultraviolet lightAlpha-MSH stimulates melanin cell production and releases melanin, which has the effect of protecting the skin from light damage 　　Afamelanotide replaces two amino acids in alpha-MSH, improving molecular stability and potency It increases the skin's melanin levels without uv rays 　　Afamelanotide has been eligible for orphan drug and priority review by the FDA 　　The efficacy of Afamelanotide was demonstrated in two clinical trial series (http:// In one trial, a total of 93 patients with red blood cell-generating protoscoccal radon were tested and 48 patients were treated with afamelanotide 　　The results showed that during the 180 days of treatment, patients in the afamelanotide group had a total of 64 hours of painless exposure, significantly higher than in the placebo group (41 hours)